# Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose

Study · id `cardio:ct-nct04460092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04460092](<https://clinicaltrials.gov/study/NCT04460092>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04460092

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04460092. Randomized; no masking; primary purpose supportive care. Start 2020-05-25 (actual); primary completion 2020-06-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04460092, source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)
- Started: 2020-05-25 (actual) (ClinicalTrials.gov record NCT04460092, source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)
- Primary completion: 2020-06-29 (anticipated) (ClinicalTrials.gov record NCT04460092, source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)
- Completion: 2020-09-25 (anticipated) (ClinicalTrials.gov record NCT04460092, source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT04460092, source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04460092-2020-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): 5-mm 32-gauge Insulin needles in the first three days of Intervention
- Intervention (Device): 8-mm 32-gauge Insulin needles in the first three days of Intervention
- Intervention (Device): 5-mm 32-gauge Insulin needles in the last three days of Intervention
- Intervention (Device): 8-mm 32-gauge Insulin needles in the last three days of Intervention
- Lead sponsor: Baqiyatallah Medical Sciences University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: f8565d8cd2dec9cb040f6b4327bb6576e1232493c6b7f756adf62c880ed97c88
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
